Clinical Trial: A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer

U.S., Dec. 17 -- ClinicalTrials.gov registry received information related to the study (NCT07284849) titled 'A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer' on Dec. 09.

Brief Summary: The purpose of this study is to evaluate the efficacy and safety of standard-of-care chemotherapy and bevacizumab with or without INCA33890 in the first-line treatment of metastatic microsatellite stable colorectal cancer.

Study Start Date: Feb. 16, 2026

Study Type: INTERVENTIONAL

Condition: CRC (Colorectal Cancer)

Intervention: DRUG: INCA33890

INCA33890 will be administered at protocol defined dose....